The effect of the HIV protease inhibitor ritonavir on proliferation, differentiation, lipogenesis, gene expression and apoptosis of human preadipocytes and adipocytes

Hormone and Metabolic Research

Volumn 37, Issue 10, 2005, Pages 602-609

  Grigem, S ^a   Fischer Posovszky, P ^a   Debatin, K M ^a   Loizon, E ^b   Vidal, H ^b   Wabitsch, Martin ^a  

^a UNIVERSITY OF ULM   (Germany)

^b INSERM   (France)

Author keywords

Fat cell; HAART; Insulin resistance; Lipodystrophy; SGBS cells

Indexed keywords

ADIPONECTIN; FATTY ACID SYNTHASE; GLUCOSE TRANSPORTER 4; INTERLEUKIN 6; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEINASE INHIBITOR; RITONAVIR; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRANSCRIPTION FACTOR;

ADIPOCYTE; ANTIVIRAL ACTIVITY; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; DRUG EFFECT; GENE EXPRESSION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; LIPOATROPHY; LIPOGENESIS; PRIORITY JOURNAL; PROADIPOCYTE; REAL TIME POLYMERASE CHAIN REACTION;

ADIPOCYTES; ADIPOGENESIS; ADIPONECTIN; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; APOPTOSIS; CELL PROLIFERATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; HIV PROTEASE INHIBITORS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; LIPOGENESIS; RITONAVIR;

HUMAN IMMUNODEFICIENCY VIRUS; MURINAE;

EID: 27744510950     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-870526     Document Type: Article

References (38)

1. Koutkia P, Grinspoon S. HIV-associated lipodystrophy: Pathogenesis, Prognosis, Treatment, and Controversies. Annu Rev Med 2004; 55: 303-317
2. Kannisto K, Sutinen J, Korsheninnikova E, Fisher RM, Ehrenborg E, Gertow K, Virkamaki A, Nyman T, Vidal H, Hamsten A, Yki-Jarvinen H. Expression of adipogenic transcription factors, peroxisome proliferators-activated receptor gamma co-activator1, IL-6 and CD45 in subcutaneous adipose tissue in lipodystrophy associated with highly active antiretroviral therapy. Aids 2003; 17: 1753-1762
3. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998; 351: 871-875
4. Carr A, Samaras K, Chisholm DJ, Cooper DA. Abnormal fat distribution and use of protease inhibitors. Lancet. 1998; 351: 1736
5. Stocker DN, Meier PJ, Stoller R, Fattinger KE. "Buffalo hump" in HIV-1 infection. Lancet. 1998; 352: 320-321
6. Acevedo M, Sprecher DL, Calabrese L, Pearce GL, Coyner DL, Halliburton SS, White RD, Sykora E, Kondos GT, Hoff JA. Pilot study of coronary atherosclerotic risk and plaque burden in HIV patients: 'a call for cardiovascular prevention'. Atherosclerosis 2002; 163: 349-354
7. Domingo P, Matias-Guiu X, Pujol RM, Francia E, Lagarda E, Sambeat MA, Vàzquez G. Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy. Aids 1999; 13: 2261-2267
8. Dowell P, Flexner C, Kwiterovich PO, Lane MD. Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors. J Biol Chem 2000; 275: 41325-41332
9. Bastard JP, Caron M, Vidal H, Jan V, Auclair M, Vigoureux C, Luboinski J, Laville M, Maachi M, Girard PM, Rozenbaum W, Levan P, Capeau J. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1 infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 2002; 359: 1026-1031
10. Caron M, Auclair M, Vigouroux C, Glorian M, Forest C, Capeau J. The HIV Protease inhibitor indinavir impairs stero regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes 2001; 50: 1378-1388
11. Zhang B, Macnaul K, Szalkowski D, Li Z, Berger J, Moller DE. Inhibition of adipocyte differentiation by HIV protease inhibitors. J Clin Endocrinol Metab 1999; 84: 4274-4277
12. Lenhard JM, Furfine ES, Jain RG, Ittoop O, Orband-Miller LA, Blanchard SG, Paulik MA, Weiel JE. HIV protease inhibitors block adipogenesis and increase lipolysis in vitro. Antiviral Res 2000; 47: 121-129
13. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000; 275: 20251-20254
14. Rudich A, Vanounou S, Riesenberg K, Porat M, Tirosh A, Harman-Boehm I, Greenberg AS, Schlaeffer F, Bashan N. The HIV protease inhibitor nelfinavir induces insulin resistance and increases basal lipolysis in 3T3-L1 adipocytes. Diabetes 2001; 50: 1425-1431
15. Wabitsch M, Brenner RE, Melzner I, Braun M, Möller P, Heinze E et al. Characterization of a human preadipocyte cell strain with high capacity for adipose differentiation. Int J Obesity 2001; 25: 8-15
16. Fischer-Posovszky P, Tornqvist H, Debatin KM, Wabitsch M. Inhibition of death-receptor mediated apoptosis in human adipocytes by the insulin-like growth factor I (IGF-I)/IGF-I receptor autocrine circuit. Endocrinology 2004; 145: 1849-1859
17. Dalen KT, Schoonjans K, Ulven SM, Weedon-Fekjaer MS, Bentzen TG, Koutnikova H, Auwerx J, Nebb HI. Adipose tissue expression of the lipid droplet-associating proteins S3-12 and perilipin is controlled by peroxisome proliferator-activated receptor-gamma. Diabetes 2004; 53: 1243-1252
18. Bao Y, Bing C, Hunter L, Jenkins JR, Wabitsch M, Trayhurn P. Zinc-alpha(2)-glycoprotein, a lipid mobilizing factor, is expressed and secreted by human (SGBS)adipocytes. FEBS Lett 2005; 579: 41-47
19. Vidal H. Quantification of lipid-related mRNAs by reverse transcription-competitive polymerase chain reaction in human white adipose tissue biopsies. Methods Mol Biol 2001; 155: 83-88
20. Flexner MD. HIV-Protease inhibitors. N Engl J Med 1998; 338: 1281-1292
21. Janneh O, Hoggard PG, Tjia JF, Jones SP, Khoo SH, Maher B, Back DJ, Pirmohamed M. Intracellular disposition and metabolic effects of zidovudine, stavudine and four protease inhibitors in cultured adipocytes. Antivir Ther 2003; 8: 417-426
22. Riddle TM, Kuhel DG, Woollett LA, Fichtenbaum CJ, Hui DY. HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J Biol Chem 2001; 276: 37514-37519
23. Nguyen AT, Gagnon A, Angel JB, Sorisky A. Ritonavir increases the level of active ADD-1/SREBP-1 protein during adipogenesis. Aids 2000; 14: 2467-2473
24. Vernochet C, Azoulay S, Duval D, Guedj R, Cottrez F, Vidal H, Ailhaud G, Dani C. Human Immunodeficiency virus protease inhibitors accumulate into cultured human adipocytes and alter expression of adipocytokines. J Biol Chem 2005; 280: 2238-2243
25. Wentworth JM, Burris TP, Chatterjee VK. HIV protease inhibitors block human preadipocyte differentiation, but not via the PPARgamma/RXR heterodimer. J Endocrinol 2000; 164: R7-R10
26. Roche R, Poizot-Martin I, Yazidi CM, Compe E, Gastaut JA, Torresani J, Planells R. Effects of antiretroviral drug combinations on the differentiation of adipocytes. Aids 2002; 16: 13-20
27. Schutt M, Zhou J, Meier M, Klein HH. Long-term effects of HIV-1 protease inhibitors on insulin secretion and insulin signaling in INS-1 beta cells. J Endocrinol 2004; 183: 445-454
28. Cammalleri C, Germinario RJ. The effects of protease inhibitors on basal and insulin-stimulated lipid metabolism, insulin binding, and signaling. J Lipid Res 2003; 44: 103-108
29. Lagathu C, Bastard JP, Auclair M, Maachi M, Kornprobst M, Capeau J, Caron M. Antiretroviral drugs with adverse effects on adipocyte lipid metabolism and survival alter the expression and secretion of proinflammatory cytokines and adiponectin in vitro. Antivir Ther 2004; 9: 911-920
30. Straub RH, Hense HW, Andus T, Scholmerich J, Riegger GA, Schunkert H. Hormone replacement therapy and interrelation between serum interleukin-6 and body mass index in postmenopausal women: a population-based study. J Clin Endocrinol Metab 2000; 85: 1340-1344
31. Kado S, Nagase T, Nagata N. Circulating levels of interleukin-6, its soluble receptor and interleukin-6/interleukin-6 receptor complex in patients with type 2 diabetes mellitus. Acta Diabetol 1999; 36: 67-72
32. Lagathu C, Bastard JP, Auclair M, Maachi M, Capeau J, Caron M. Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. Biochem Biophys Res Commun 2003; 311: 372-379
33. Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 2003; 278: 45777-45784
34. Haque WA, Shimomura I, Matsuzawa Y, Garg A. Serum adiponectin and leptin levels in patients with lipodystrophy. J Clin Endocrinol Metab 2002; 87: 2395-2398
35. Mynarcik DC, Combs T, McNurlan MA, Scherer PE, Komaroff E, Gelato MC. Adiponectin and leptin levels in HIV-infected subjects with insulin resistance and body fat redistribution. J Acquir Immune Defic Syndr 2002; 31: 514-520
36. Fasshauer M, Kralisch S, Klier M, Lossner U, Bluher M, Klein J, Paschke R. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2003; 301: 1045-1050
37. Gustafson B, Jack MM, Cushman SW, Smith U. Adiponectin gene activation by thiazolidinediones requires PPAR gamma 2, but not C/EBPalpha-evidence for differential regulation of the aP2 and adiponectin genes. Biochem Biophys Res Commun 2003; 308: 933-939
38. Ledru E, Christeff N, Patey O, de Truchis P, Melchior JC, Gougeon ML. Alteration of tumor necrosis factor-alpha T-cell homeostasis following potent antiretroviral therapy: contribution to the development of human immunodeficiency virus-associated lipodystrophy syndrome. Blood 2000; 95: 3191-3198